Skip to main content
. Author manuscript; available in PMC: 2022 May 18.
Published in final edited form as: Gastroenterology. 2021 Feb 9;160(6):2181–2183.e1. doi: 10.1053/j.gastro.2021.02.014

Table.

Antimicrobial resistance, treatment regimens and eradication success percentages

Antimicrobial (189 isolates) Resistance(%)
  Resistance to ≥ 1 antimicrobials 65.6
  Metronidazole 33.3
  Clarithromycin 30.0
  Levofloxacin 29.6
  Amoxicillin 1.1
  Rifabutin 0.5
  Tetracycline 0.5
Co-resistance patterns (124 isolates resistant to ≥ 1 antimicrobials)
  Clarithromycin-Metronidazole-Levofloxacin 9.7
  Metronidazole-Levofloxacin 8.1
  Clarithromycin - Metronidazole 7.3
  Clarithromycin -Levofloxacin 7.3
  Clarithromycin- Levofloxacin-Tetracycline 0.8
  Metronidazole-Levofloxacin-Amoxicillin 0.8

Treatment regimen* (Total [%]) Eradication Success (%)
 All treatment regimens (187 [100]) 75.4
 Quadruple regimens
  PPI-Tetracycline-Metronidazole-Bismuth (79 [42.2]) 89.9
  PPI-Doxycycline-Metronidazole-Bismuth (18 [14.1]) 83.3
  PPI-Clarithromycin- Amoxicillin-Metronidazole (4 [3.1]) 75.0
 Triple regimens
  PPI-Clarithromycin- Amoxicillin (62 [48.4]) 58.1
  PPI-Clarithromycin- Metronidazole (18 [14.1]) 61.1
  PPI-Amoxicillin-Metronidazole (4 [3.1]) 100
  PPI-Rifabutin-Amoxicillin (2 [1.6]) 50.0
*

187 isolates with data on treatment regimen and eradication test

PPI: proton pump inhibitor